Genomtec reported continued losses in Q3 2024 as it advances its Genomtec ID and oncology projects, relying on grants and a recent share issue for funding. M&A discussions and patent grants marked key developments, with commercialisation still pending.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.